Dr Harish Iyer, CEO, Shantha Biotechnics
Sanofi's Shantha's human insulin, Insuman, is used in treating patients with type 1 & 2 diabetes, which demands insulin. The company has licensed the product in about 90 countries ever since its first introduction 17 years ago.
The manufacturing site is said to be spread across 13,400 square meters. The site is expected to have the capability of manufacturing up to 60 million cartridges per year.
According to the company, the unit will start its commercial manufacturing by 2019, and supplying to the regulated markets by 2020.
The company has a similar manufacturing facility located in Frankfurt, Germany. Insuman is a ‘tech-transfer' project from Sanofi Frankfurt, using state-of-the-art Isolator technology.